The APPL1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population engineered for targeted disruption of the APPL1 gene in the HAP1 human cell line. This loss-of-function model enables robust investigation of APPL1-dependent signaling without single-cell cloning. The polyclonal format provides a heterogeneous pool of edited cells, ideal for studying gene function in membrane receptor signaling and intracellular trafficking.
HAP1 is a near-haploid human cell line derived from KBM-7 chronic myeloid leukemia cells, featuring a predominantly haploid karyotype and defective p53. This genetic simplicity streamlines CRISPR/Cas9-mediated gene disruption and reduces redundancy, making HAP1 a preferred host for knockout studies of membrane protein function and signaling pathways.
APPL1 encodes an adaptor protein that links activated membrane receptors such as the insulin receptor, adiponectin receptors 1/2, EGFR, and TrkA to downstream kinases including AKT1, GSK3??, mTOR, and ERK1/2. It interacts with PIK3R1 to recruit PI3K and binds Rab5 on early endosomes, integrating insulin and adiponectin signals with endosomal trafficking. APPL1 also scaffolds the NuRD complex and modulates NF-??B, positioning it at a nexus of metabolic and survival pathways. Disruption of APPL1 impairs insulin-stimulated AKT phosphorylation and endosomal signaling, affecting glucose metabolism and cell survival.
In the HAP1 near-haploid background, APPL1 knockout yields a uniform loss-of-function population despite polyclonal editing, enabling clean dissection of endosomal adaptor function. Researchers can use these cells to study how APPL1 coordinates insulin and adiponectin receptor signaling to metabolic effectors and to explore its role in endosomal compartmentalization of signal transduction. The defective p53 status also facilitates investigation of APPL1 in cancer-related pathways without confounding apoptotic responses.
Typical applications encompass insulin and adiponectin signaling studies using phospho-AKT and phospho-ERK Western blotting, immunofluorescence for APPL1 endosomal localization, glucose uptake assays, and co-immunoprecipitation of APPL1-interacting factors such as APPL2, Rab5, and the NuRD complex. Migration assays and drug sensitivity profiling with PI3K/AKT inhibitors (e.g., wortmannin, MK-2206) support cancer metabolism and drug target validation. For further technical details, please contact Ascent Research.
